These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 27000662)

  • 21. Molecular Subtypes of Prostate Cancer.
    Arora K; Barbieri CE
    Curr Oncol Rep; 2018 Jun; 20(8):58. PubMed ID: 29858674
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metastasis-Directed Therapy for Oligometastatic Castration-Sensitive Prostate Cancer: An Alternative to ADT?
    Cahill EM; Pfail JL; Fu MZ; Saraiya B; Mayer T; Stephenson RD; Ennis RD; Hathout L; Deek MP; Ghodoussipour S; Jang TL
    Curr Urol Rep; 2023 Jul; 24(7):299-306. PubMed ID: 37017928
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations.
    Sowalsky AG; Ye H; Bhasin M; Van Allen EM; Loda M; Lis RT; Montaser-Kouhsari L; Calagua C; Ma F; Russo JW; Schaefer RJ; Voznesensky OS; Zhang Z; Bubley GJ; Montgomery B; Mostaghel EA; Nelson PS; Taplin ME; Balk SP
    Cancer Res; 2018 Aug; 78(16):4716-4730. PubMed ID: 29921690
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer.
    Wyatt AW; Azad AA; Volik SV; Annala M; Beja K; McConeghy B; Haegert A; Warner EW; Mo F; Brahmbhatt S; Shukin R; Le Bihan S; Gleave ME; Nykter M; Collins CC; Chi KN
    JAMA Oncol; 2016 Dec; 2(12):1598-1606. PubMed ID: 27148695
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genomic and phenotypic heterogeneity in prostate cancer.
    Haffner MC; Zwart W; Roudier MP; True LD; Nelson WG; Epstein JI; De Marzo AM; Nelson PS; Yegnasubramanian S
    Nat Rev Urol; 2021 Feb; 18(2):79-92. PubMed ID: 33328650
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.
    Klein EA; Yousefi K; Haddad Z; Choeurng V; Buerki C; Stephenson AJ; Li J; Kattan MW; Magi-Galluzzi C; Davicioni E
    Eur Urol; 2015 Apr; 67(4):778-86. PubMed ID: 25466945
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer.
    Gupta S; Halabi S; Kemeny G; Anand M; Giannakakou P; Nanus DM; George DJ; Gregory SG; Armstrong AJ
    Mol Cancer Res; 2021 Jun; 19(6):1040-1050. PubMed ID: 33771885
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Unpacking circulating tumor DNA lends insight into prostate cancer biology and the clonal dynamics of metastasis.
    Takeda DY; Sowalsky AG
    Cancer Cell; 2022 Oct; 40(10):1086-1088. PubMed ID: 36179684
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clonal Evolution and Epithelial Plasticity in the Emergence of AR-Independent Prostate Carcinoma.
    Laudato S; Aparicio A; Giancotti FG
    Trends Cancer; 2019 Jul; 5(7):440-455. PubMed ID: 31311658
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The HIF1A functional genetic polymorphism at locus +1772 associates with progression to metastatic prostate cancer and refractoriness to hormonal castration.
    Fraga A; Ribeiro R; Príncipe P; Lobato C; Pina F; Maurício J; Monteiro C; Sousa H; Calais da Silva F; Lopes C; Medeiros R
    Eur J Cancer; 2014 Jan; 50(2):359-65. PubMed ID: 24090974
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adaptation and clonal selection models of castration-resistant prostate cancer: current perspective.
    Ahmed M; Li LC
    Int J Urol; 2013 Apr; 20(4):362-71. PubMed ID: 23163774
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Non-Coding RNAs Set a New Phenotypic Frontier in Prostate Cancer Metastasis and Resistance.
    Altschuler J; Stockert JA; Kyprianou N
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672595
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
    Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N
    Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Androgen deprivation therapy for the treatment of prostate cancer: a focus on pharmacokinetics.
    Polotti CF; Kim CJ; Chuchvara N; Polotti AB; Singer EA; Elsamra S
    Expert Opin Drug Metab Toxicol; 2017 Dec; 13(12):1265-1273. PubMed ID: 29137489
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Caveolin-1 mediates testosterone-stimulated survival/clonal growth and promotes metastatic activities in prostate cancer cells.
    Li L; Yang G; Ebara S; Satoh T; Nasu Y; Timme TL; Ren C; Wang J; Tahir SA; Thompson TC
    Cancer Res; 2001 Jun; 61(11):4386-92. PubMed ID: 11389065
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Understanding heterogeneity of treatment effect in prostate cancer.
    Aly A; Mullins CD; Hussain A
    Curr Opin Oncol; 2015 May; 27(3):209-16. PubMed ID: 25689354
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue.
    Cooper CS; Eeles R; Wedge DC; Van Loo P; Gundem G; Alexandrov LB; Kremeyer B; Butler A; Lynch AG; Camacho N; Massie CE; Kay J; Luxton HJ; Edwards S; Kote-Jarai Z; Dennis N; Merson S; Leongamornlert D; Zamora J; Corbishley C; Thomas S; Nik-Zainal S; O'Meara S; Matthews L; Clark J; Hurst R; Mithen R; Bristow RG; Boutros PC; Fraser M; Cooke S; Raine K; Jones D; Menzies A; Stebbings L; Hinton J; Teague J; McLaren S; Mudie L; Hardy C; Anderson E; Joseph O; Goody V; Robinson B; Maddison M; Gamble S; Greenman C; Berney D; Hazell S; Livni N; ; Fisher C; Ogden C; Kumar P; Thompson A; Woodhouse C; Nicol D; Mayer E; Dudderidge T; Shah NC; Gnanapragasam V; Voet T; Campbell P; Futreal A; Easton D; Warren AY; Foster CS; Stratton MR; Whitaker HC; McDermott U; Brewer DS; Neal DE
    Nat Genet; 2015 Apr; 47(4):367-372. PubMed ID: 25730763
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantitative proteomics reveals that enzymes of the ketogenic pathway are associated with prostate cancer progression.
    Saraon P; Cretu D; Musrap N; Karagiannis GS; Batruch I; Drabovich AP; van der Kwast T; Mizokami A; Morrissey C; Jarvi K; Diamandis EP
    Mol Cell Proteomics; 2013 Jun; 12(6):1589-601. PubMed ID: 23443136
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Spatial Intratumor Genomic Heterogeneity within Localized Prostate Cancer Revealed by Single-nucleus Sequencing.
    Su F; Zhang W; Zhang D; Zhang Y; Pang C; Huang Y; Wang M; Cui L; He L; Zhang J; Zou L; Zhang J; Li W; Li L; Shao J; Ma J; Xiao F; Liu M
    Eur Urol; 2018 Nov; 74(5):551-559. PubMed ID: 29941308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.